CBI Share Price Performance
₪0.38
0.01 (1.86%)
Price ₪0.38
Share Price₪0.38
Would Clal Biotechnology Industries (TLV:CBI) Be Better Off With Less Debt?
Sep 08
Clal Biotechnology Industries Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
CBI Community Narratives
There are no narratives available yet.
Recent CBI News & Updates
Clal Biotechnology Industries Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.20
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 52.9%
Clal Biotechnology Industries Ltd. Competitors
Snowflake Analysis
About CBI
- Founded
- 1998
- Employees
- n/a
- CEO
- WebsiteView website
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel. It operates as a former subsidiary of Clal Industries and Investments Ltd.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Israeli Market Performance
- 7 Days: -0.8%
- 3 Months: 1.1%
- 1 Year: 58.4%
- Year to Date: 30.3%
The Utilities sector gained 5.7% while the market remained flat over the last week. Meanwhile, the market is actually up 58% over the past year. Earnings are forecast to grow by 16% annually. Market details ›